Kang Fang Biotech announced that in the first half of 2026, the Group's revenue was RMB 1,806 million, up 27.92% year on year; commercial sales revenue was RMB 1,803 million, up 28.65% year on year; the Group lost RMB 447 million and lost RMB 588 million for the same period in 2025.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.